- U0126 is a highly selective and potent non-ATP competitive MEK1/2 inhibitor that has become a valuable tool in research studying the MAPK/ERK signaling pathway. This small molecule compound was first described in 1998 and has since become one of the most widely used MEK inhibitors in laboratory research.
- Chemically, U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene) is an organic compound that functions by binding to MEK1/2, preventing their catalytic activity and subsequent phosphorylation of ERK1/2. Unlike many kinase inhibitors that compete with ATP binding, U0126 acts through an allosteric mechanism, binding to a site distinct from the ATP-binding pocket.
- The compound demonstrates high specificity for MEK1/2, with IC50 values in the nanomolar range (IC50 = 72 nM for MEK1 and 58 nM for MEK2). This selectivity makes U0126 particularly valuable for studying MEK-dependent cellular processes and distinguishing them from other signaling pathways. It shows significantly less activity against other kinases, including other members of the MAPK family.
- In cellular systems, U0126 effectively blocks ERK1/2 phosphorylation and activation, leading to inhibition of various cellular processes including proliferation, differentiation, and survival in many cell types. The compound is cell-permeable and shows rapid inhibition of MEK activity in cultured cells, typically at concentrations between 10-50 µM.
- U0126 has been extensively used in research to elucidate the role of MEK/ERK signaling in various biological processes, including cell cycle progression, apoptosis, gene expression, and cellular differentiation. It has been particularly valuable in cancer research, helping to establish the importance of the RAF-MEK-ERK pathway in tumor cell growth and survival.
- Despite its widespread use in research, U0126 has some limitations. It shows relatively poor solubility in aqueous solutions and requires dissolution in organic solvents such as DMSO. The compound can also be unstable in solution and may degrade under certain conditions, particularly in the presence of strong reducing agents or when exposed to light.
- While U0126 itself has not been developed as a therapeutic agent, its success as a research tool has helped pave the way for the development of clinical MEK inhibitors. The insights gained from studies using U0126 have contributed significantly to our understanding of MEK inhibition as a therapeutic strategy in cancer treatment.
Reliability Index *****
Note: If you notice any errors or inconsistencies, we welcome your feedback. Please share your observations in the comment box below — your input helps us improve.
Highest reliability: *****
Lowest reliability: *****
